JP7166929B2 - イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用 - Google Patents

イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用 Download PDF

Info

Publication number
JP7166929B2
JP7166929B2 JP2018554375A JP2018554375A JP7166929B2 JP 7166929 B2 JP7166929 B2 JP 7166929B2 JP 2018554375 A JP2018554375 A JP 2018554375A JP 2018554375 A JP2018554375 A JP 2018554375A JP 7166929 B2 JP7166929 B2 JP 7166929B2
Authority
JP
Japan
Prior art keywords
inhalation
magnesium isoglycyrrhizinate
lactose
nebulizer
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511556A5 (enExample
JPWO2017177966A5 (enExample
JP2019511556A (ja
Inventor
グウ，ホンメイ
ワン，シャンチュン
チャン，シーチュエン
ファン，レイ
シュウ，ホンジャン
ソン，ウェイ
ドン，ピン
スン，ジョンイン
チャン，イン
チェン，ドォヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2019511556A publication Critical patent/JP2019511556A/ja
Publication of JP2019511556A5 publication Critical patent/JP2019511556A5/ja
Priority to JP2021126412A priority Critical patent/JP7309791B2/ja
Publication of JPWO2017177966A5 publication Critical patent/JPWO2017177966A5/ja
Application granted granted Critical
Publication of JP7166929B2 publication Critical patent/JP7166929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018554375A 2016-04-15 2017-04-14 イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用 Active JP7166929B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021126412A JP7309791B2 (ja) 2016-04-15 2021-08-02 イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610237175.3 2016-04-15
CN201610237175 2016-04-15
PCT/CN2017/080583 WO2017177966A1 (zh) 2016-04-15 2017-04-14 异甘草酸或其盐的吸入制剂及其在制备治疗呼吸系统疾病药物中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021126412A Division JP7309791B2 (ja) 2016-04-15 2021-08-02 イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用

Publications (4)

Publication Number Publication Date
JP2019511556A JP2019511556A (ja) 2019-04-25
JP2019511556A5 JP2019511556A5 (enExample) 2020-05-21
JPWO2017177966A5 JPWO2017177966A5 (enExample) 2022-06-23
JP7166929B2 true JP7166929B2 (ja) 2022-11-08

Family

ID=60042326

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018554375A Active JP7166929B2 (ja) 2016-04-15 2017-04-14 イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用
JP2021126412A Active JP7309791B2 (ja) 2016-04-15 2021-08-02 イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021126412A Active JP7309791B2 (ja) 2016-04-15 2021-08-02 イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用

Country Status (13)

Country Link
US (2) US20190117568A1 (enExample)
EP (1) EP3443954A4 (enExample)
JP (2) JP7166929B2 (enExample)
KR (1) KR102410183B1 (enExample)
CN (2) CN111920785B (enExample)
AU (1) AU2017251548B2 (enExample)
BR (1) BR112018071208A2 (enExample)
EA (1) EA201892350A1 (enExample)
MX (1) MX394106B (enExample)
MY (1) MY204600A (enExample)
PH (1) PH12018502195A1 (enExample)
SG (2) SG11201809042SA (enExample)
WO (1) WO2017177966A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119345161A (zh) * 2024-12-25 2025-01-24 江苏长泰药业股份有限公司 一种丙酮酸钠雾化吸入制剂及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004914A1 (ja) 2003-07-09 2005-01-20 Anges Mg, Inc. NF-κBデコイを含む呼吸器疾患用治療および予防のための薬学的組成物およびその使用方法
CN101190232A (zh) 2006-11-30 2008-06-04 江苏正大天晴药业股份有限公司 一种注射用异甘草酸镁冻干粉针剂及其制备方法
JP2009513529A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
CN103156930A (zh) 2011-12-19 2013-06-19 张亚军 一种含芍药和甘草提取物的呼吸道给药制剂
JP2015509972A (ja) 2012-03-13 2015-04-02 レスピバート・リミテツド 新規製薬学的製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891221A (en) * 1988-11-23 1990-01-02 Edward Shanborm Whole blood antiviral process and composition
CN101023953B (zh) * 2006-07-24 2010-05-12 南开大学 治疗支气管哮喘的组合物
JP2008222682A (ja) * 2007-03-15 2008-09-25 Kumamoto Univ 線維化肺疾患治療薬、気道粘液分泌細胞過形成抑制剤および気道塞栓治療薬
CN101396368B (zh) * 2007-09-29 2010-12-01 江苏正大天晴药业股份有限公司 异甘草酸或其盐在制备治疗过敏性鼻炎药物中的应用
CN101669962A (zh) * 2009-09-18 2010-03-17 杭州市第六人民医院 复合甘草酸氨基酸注射液及其制备方法和应用
WO2012026928A1 (en) * 2010-08-25 2012-03-01 Diacarta Llc Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CN102920936A (zh) * 2012-09-17 2013-02-13 陈泉生 一种治疗呼吸道疾病的吸盐物及其制作方法
CN104042573A (zh) * 2014-06-03 2014-09-17 青岛市市立医院 一种异甘草酸镁冻干粉针剂及其制备方法
CN106237297A (zh) * 2016-08-30 2016-12-21 吉林紫鑫药业股份有限公司 一种用于治疗慢性支气管炎的药物组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004914A1 (ja) 2003-07-09 2005-01-20 Anges Mg, Inc. NF-κBデコイを含む呼吸器疾患用治療および予防のための薬学的組成物およびその使用方法
JP2009513529A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
CN101190232A (zh) 2006-11-30 2008-06-04 江苏正大天晴药业股份有限公司 一种注射用异甘草酸镁冻干粉针剂及其制备方法
CN103156930A (zh) 2011-12-19 2013-06-19 张亚军 一种含芍药和甘草提取物的呼吸道给药制剂
JP2015509972A (ja) 2012-03-13 2015-04-02 レスピバート・リミテツド 新規製薬学的製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
別冊・医学のあゆみ 呼吸器疾患，1991年，246-249

Also Published As

Publication number Publication date
SG11201809042SA (en) 2018-11-29
AU2017251548A1 (en) 2018-11-15
PH12018502195A1 (en) 2019-09-23
CN111920785B (zh) 2022-05-20
KR102410183B1 (ko) 2022-06-17
BR112018071208A2 (pt) 2019-02-12
US20190117568A1 (en) 2019-04-25
WO2017177966A1 (zh) 2017-10-19
KR20180132143A (ko) 2018-12-11
SG10202010192YA (en) 2020-11-27
US11534398B2 (en) 2022-12-27
EP3443954A4 (en) 2019-11-20
MY204600A (en) 2024-09-05
CN111920785A (zh) 2020-11-13
CN109069442A (zh) 2018-12-21
JP2019511556A (ja) 2019-04-25
CN109069442B (zh) 2020-09-04
AU2017251548B2 (en) 2022-02-17
JP2021176903A (ja) 2021-11-11
EA201892350A1 (ru) 2019-06-28
JP7309791B2 (ja) 2023-07-18
MX394106B (es) 2025-03-24
EP3443954A1 (en) 2019-02-20
MX2018012461A (es) 2019-09-18
US20200368158A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
US8168598B2 (en) Optimised formulation of tobramycin for aerosolization
JP2023086774A (ja) 乾燥粉末配合および使用方法
JP2012522009A (ja) 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
KR20120015295A (ko) 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형
PL190782B1 (pl) Nowe zastosowanie budesonidu i formoterolu
KR19990071975A (ko) 신규한복합조성물
JP2021529771A (ja) クロモリンナトリウムおよびα−ラクトースの粉末製剤
AU2015261103A1 (en) Combinations of tiotropium bromide, formoterol and budesonide for the treatment of COPD
IT202000005026A1 (it) Lattoferrina per uso inalatorio ad azione antivirale
US20030053956A1 (en) Alkylaryl polyether alcohol polymers for treatment and prophylaxis of snoring, sleep apnea, sudden infant death syndrome and for improvement of nasal breathing
CN112533589A (zh) 用于治疗粘液高分泌的含有粘液溶解剂的组合物及其给药装置
JP7309791B2 (ja) イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの使用
US20050053553A1 (en) Combined doses of formoterol and fluticasone
JP2021176903A5 (enExample)
EA009935B1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол
JPWO2017177966A5 (enExample)
TW201016215A (en) Compositions and uses of antiviral active pharmaceutical agents
WO2001012192A2 (en) Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil
RU2614716C2 (ru) Фармацевтическая композиция для применения назальным введением, содержащая кортикостероид и хинолон или фузидовую кислоту
HK1261173B (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use of the inhaled preparation
HK1261173A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use of the inhaled preparation
EA040563B1 (ru) Применение препарата для ингаляции на основе изоглицирризината магния для лечения заболеваний дыхательной системы
WO2022166724A1 (zh) 一种福多司坦吸入用溶液制剂及其制备方法和用途
WO2021211854A1 (en) Inhalable formulation of a solution containing tiotropium bromide
AU2002247032A1 (en) Alkyl aryl polyether alcohol polymers for improvement of nasal breathing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221026

R150 Certificate of patent or registration of utility model

Ref document number: 7166929

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150